Cognitive function is an important end point of treatments in dementia clinical trials. Measuring cognitive function by standardized tests, however, is biased toward highly constrained environments (such as hospitals) in selected samples. Patient-powered real-world evidence using information and communication technology devices, including environmental and wearable sensors, may help to overcome these limitations. This position paper describes current and novel information and communication technology devices and algorithms to monitor behavior and function in people with prodromal and manifest stages of dementia continuously, and discusses clinical, technological, ethical, regulatory, and user-centered requirements for collecting real-world evidence in future randomized controlled trials. Challenges of data safety, quality, and privacy and regulatory requirements need to be addressed by future smart sensor technologies. When these requirements are satisfied, these technologies will provide access to truly user relevant outcomes and broader cohorts of participants than currently sampled in clinical trials.

Use of nonintrusive sensor-based information and communication technology for real-world evidence for clinical trials in dementia / Teipel, Stefan; König, Alexandra; Hoey, Jesse; Kaye, Jeff; Krüger, Frank; Robillard, Julie M.; Kirste, Thomas; Babiloni, Claudio. - In: ALZHEIMER'S & DEMENTIA. - ISSN 1552-5260. - 14:9(2018), pp. 1216-1231. [10.1016/j.jalz.2018.05.003]

Use of nonintrusive sensor-based information and communication technology for real-world evidence for clinical trials in dementia

Babiloni, Claudio
2018

Abstract

Cognitive function is an important end point of treatments in dementia clinical trials. Measuring cognitive function by standardized tests, however, is biased toward highly constrained environments (such as hospitals) in selected samples. Patient-powered real-world evidence using information and communication technology devices, including environmental and wearable sensors, may help to overcome these limitations. This position paper describes current and novel information and communication technology devices and algorithms to monitor behavior and function in people with prodromal and manifest stages of dementia continuously, and discusses clinical, technological, ethical, regulatory, and user-centered requirements for collecting real-world evidence in future randomized controlled trials. Challenges of data safety, quality, and privacy and regulatory requirements need to be addressed by future smart sensor technologies. When these requirements are satisfied, these technologies will provide access to truly user relevant outcomes and broader cohorts of participants than currently sampled in clinical trials.
2018
epidemiology; health policy; developmental neuroscience; neurology (clinical); geriatrics and gerontology; cellular and molecular neuroscience; psychiatry and mental health
01 Pubblicazione su rivista::01a Articolo in rivista
Use of nonintrusive sensor-based information and communication technology for real-world evidence for clinical trials in dementia / Teipel, Stefan; König, Alexandra; Hoey, Jesse; Kaye, Jeff; Krüger, Frank; Robillard, Julie M.; Kirste, Thomas; Babiloni, Claudio. - In: ALZHEIMER'S & DEMENTIA. - ISSN 1552-5260. - 14:9(2018), pp. 1216-1231. [10.1016/j.jalz.2018.05.003]
File allegati a questo prodotto
File Dimensione Formato  
Teipel_Use_2018.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 569.64 kB
Formato Adobe PDF
569.64 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1179609
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 41
social impact